Loading
A phase 3 trial of Zolbetuximab, Pembrolizumab, Capecitabine, Oxaliplatin, Leucovorin (folinic acid) and Fluorouracil (5-FU) in gastric & gastro-oesophageal junction cancer, run by Astellas Pharma Global Development, Inc., now recruiting.
A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer is a phase 3 interventional study registered as NCT06901531 by Astellas Pharma Global Development, Inc., with 500 participants planned, started 2025-05-22 and due to reach its primary completion in 2028-09-30. Interventions recorded: zolbetuximab, Pembrolizumab, Capecitabine, Oxaliplatin, Folinic acid (leucovorin or local equivalent) and 5-fluorouracil (5-FU).
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Zolbetuximab, Astellas, Leucovorin (folinic acid), Oxaliplatin and the tag pipeline.
Shares Oxaliplatin, Fluorouracil (5-FU), Capecitabine, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Shares Oxaliplatin, Fluorouracil (5-FU), Capecitabine, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Shares Oxaliplatin, Capecitabine, Monoclonal antibodies, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Shares Oxaliplatin, Capecitabine, Monoclonal antibodies, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Shares Oxaliplatin, Capecitabine, Monoclonal antibodies, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Shares Zolbetuximab, Astellas, Monoclonal antibodies and the tag pipeline.
Shares Leucovorin (folinic acid), Oxaliplatin, Capecitabine and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/